Biocon Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Biocon Ltd is ₹ 401.5 as of 12 May 13:35 . The P/E Ratio of Biocon Ltd changed from 66.3 on March 2021 to 40.4 on March 2025 . This represents a CAGR of -9.43% over 5 yearsThe P/E Ratio of Corona Remedies Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Biocon Ltd changed from ₹ 49056 crore on March 2021 to ₹ 40964 crore on March 2025 . This represents a CAGR of -3.54% over 5 yearsThe Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Biocon Ltd for the Mar '26 is ₹ 4569 crore as compare to the Dec '25 revenue of ₹ 4290 crore. This represent the growth of 6.5% The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The ebitda of Biocon Ltd for the Mar '26 is ₹ 992.4 crore as compare to the Dec '25 ebitda of ₹ 657.4 crore. This represent the growth of 50.96% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The net profit of Biocon Ltd changed from ₹ 861.8 crore to ₹ 198.6 crore over 8 quarters. This represents a CAGR of -52.00% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
Also in the same year, the company had received US funding for proprietary technologies.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Biocon Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Biocon Ltd or Corona Remedies Ltd?

Market cap of Biocon Ltd is 63,296 Cr while Market cap of Corona Remedies Ltd is 10,722 Cr

What are the key factors driving the stock performance of Biocon Ltd and Corona Remedies Ltd?

The stock performance of Biocon Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Corona Remedies Ltd?

As of May 12, 2026, the Biocon Ltd stock price is INR ₹390.5. On the other hand, Corona Remedies Ltd stock price is INR ₹1753.2.

How do dividend payouts of Biocon Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Biocon Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.